ES2378976B1 - Anticuerpo contra ephrin b2 y su uso. - Google Patents

Anticuerpo contra ephrin b2 y su uso. Download PDF

Info

Publication number
ES2378976B1
ES2378976B1 ES201031402A ES201031402A ES2378976B1 ES 2378976 B1 ES2378976 B1 ES 2378976B1 ES 201031402 A ES201031402 A ES 201031402A ES 201031402 A ES201031402 A ES 201031402A ES 2378976 B1 ES2378976 B1 ES 2378976B1
Authority
ES
Spain
Prior art keywords
gly
ser
leu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201031402A
Other languages
English (en)
Spanish (es)
Other versions
ES2378976A1 (es
Inventor
Jorge Luis MARTÍNEZ TORRECUADRADA
María Ángeles ABENGOZAR INFANTES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro Nacional de Investigaciones Oncologicas CNIO
Original Assignee
Centro Nacional de Investigaciones Oncologicas CNIO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201031402A priority Critical patent/ES2378976B1/es
Application filed by Centro Nacional de Investigaciones Oncologicas CNIO filed Critical Centro Nacional de Investigaciones Oncologicas CNIO
Priority to PCT/ES2011/070655 priority patent/WO2012038573A1/es
Priority to CA2812727A priority patent/CA2812727A1/en
Priority to AU2011306816A priority patent/AU2011306816A1/en
Priority to CN2011800534643A priority patent/CN103237812A/zh
Priority to KR1020137007045A priority patent/KR20140014062A/ko
Priority to MX2013003168A priority patent/MX2013003168A/es
Priority to JP2013528731A priority patent/JP2013542720A/ja
Priority to RU2013118454/10A priority patent/RU2013118454A/ru
Priority to BR112013005977A priority patent/BR112013005977A2/pt
Priority to US13/824,171 priority patent/US9062109B2/en
Priority to EP11826446.4A priority patent/EP2620449A4/en
Publication of ES2378976A1 publication Critical patent/ES2378976A1/es
Application granted granted Critical
Publication of ES2378976B1 publication Critical patent/ES2378976B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201031402A 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso. Expired - Fee Related ES2378976B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
RU2013118454/10A RU2013118454A (ru) 2010-09-21 2011-09-20 Антитело к эфрину в2 и его применение
AU2011306816A AU2011306816A1 (en) 2010-09-21 2011-09-20 Anti-ephrin-B2 antibody and use thereof
CN2011800534643A CN103237812A (zh) 2010-09-21 2011-09-20 Ephrin B2抗体及其应用
KR1020137007045A KR20140014062A (ko) 2010-09-21 2011-09-20 항-에프린 ｂ2 항체 및 이의 용도
MX2013003168A MX2013003168A (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso.
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso
CA2812727A CA2812727A1 (en) 2010-09-21 2011-09-20 Anti-ephrin b2 antibody and its use
BR112013005977A BR112013005977A2 (pt) 2010-09-21 2011-09-20 polipeptídeo isolado, anticorpo contra efrina-b2 e sua utilização, ácido nucleíco; vetor; célula; método de obtenção do polipeptídeo ou do anticorpo; método de detecção e/ou quantificação da efrina-b2; método de diagnóstico de uma enfermidade associada a expressão da efrina-b2; composição e sua utilização
US13/824,171 US9062109B2 (en) 2010-09-21 2011-09-20 Anti-ephrin-B2 antibody and compositions comprising it
EP11826446.4A EP2620449A4 (en) 2010-09-21 2011-09-20 Anti-ephrin-b2 antibody and use thereof
JP2013528731A JP2013542720A (ja) 2010-09-21 2011-09-20 抗エフリン−ｂ２抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.

Publications (2)

Publication Number Publication Date
ES2378976A1 ES2378976A1 (es) 2012-04-19
ES2378976B1 true ES2378976B1 (es) 2013-05-06

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201031402A Expired - Fee Related ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.

Country Status (12)

Country Link
US (1) US9062109B2 (https=)
EP (1) EP2620449A4 (https=)
JP (1) JP2013542720A (https=)
KR (1) KR20140014062A (https=)
CN (1) CN103237812A (https=)
AU (1) AU2011306816A1 (https=)
BR (1) BR112013005977A2 (https=)
CA (1) CA2812727A1 (https=)
ES (1) ES2378976B1 (https=)
MX (1) MX2013003168A (https=)
RU (1) RU2013118454A (https=)
WO (1) WO2012038573A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
EP3969478A1 (en) * 2019-05-14 2022-03-23 Sanford Health Anti-human ephrin b1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
WO2025207820A2 (en) * 2024-03-27 2025-10-02 Mediar Therapeutics, Inc. Anti-ephrin b2 antibodies and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
AU2006308648A1 (en) * 2005-10-31 2007-05-10 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
AR059096A1 (es) * 2006-01-20 2008-03-12 Genentech Inc Anticuerpos anti- efrina -b2 y metodos que usan estos
ES2368764T3 (es) * 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Also Published As

Publication number Publication date
US9062109B2 (en) 2015-06-23
ES2378976A1 (es) 2012-04-19
MX2013003168A (es) 2013-08-21
KR20140014062A (ko) 2014-02-05
EP2620449A4 (en) 2014-03-26
CN103237812A (zh) 2013-08-07
EP2620449A1 (en) 2013-07-31
WO2012038573A1 (es) 2012-03-29
JP2013542720A (ja) 2013-11-28
US20130287795A1 (en) 2013-10-31
CA2812727A1 (en) 2012-03-29
RU2013118454A (ru) 2014-10-27
BR112013005977A2 (pt) 2019-09-24
AU2011306816A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
ES3028882T3 (en) Agents, uses and methods for the treatment of synucleinopathy
CN108602888B (zh) 抑制癌症生长的结合分子
ES2938628T3 (es) Agentes de unión a VEGF/DLL4 y usos de los mismos
ES2952132T3 (es) Nuevo anticuerpo anti-pad4
ES2435917T3 (es) Anticuerpos anti-Trk-A y derivados de los mismos
ES2707599T3 (es) Anticuerpos anti-asic1 y usos de los mismos
ES2818184T3 (es) Anticuerpo anti-Notch 4 humano
ES2846400T3 (es) Anticuerpos que se unen a un polipéptido PRL-1 o PRL-3 intracelular
CN109310756A (zh) 新型血管生成素2，vegf双特异性拮抗剂
ES2724364T3 (es) Procedimiento de tratamiento de fibrosis pulmonar idiopática
ES2378976B1 (es) Anticuerpo contra ephrin b2 y su uso.
ES2818948T3 (es) Composiciones para la supresión del cáncer por inhibición de TMCC3
EA035586B1 (ru) Новые антиангиогенные слитые белки
ES2768335T3 (es) Anticuerpos humanos anti-IL-32
ES2913162T3 (es) Anticuerpo anti-Myl9
CN110627905B (zh) 靶向vegf与egfr的双功能融合蛋白及其应用
WO2023016509A1 (zh) 抑制肿瘤细胞转移的药物及其用途
US20220195037A1 (en) Compositions and methods for inhibiting cancer stem cells
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
Liu et al. Novel Abs targeting the N‐terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile‐acid‐related side‐effects
US20210155709A1 (en) Antibodies anti tumor associated antigens and method for obtaining them
ES2865303T3 (es) Ligante de adrenomedulina para su uso en la terapia del cáncer
CN116964086A (zh) 抗SARS-CoV-2抗体和其用途
KR20220092859A (ko) 항-cxcr2 항체 및 이의 용도
KR20250123919A (ko) 항-tgf베타 수용체 1 항체 및 그의 용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2378976

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130506

FD2A Announcement of lapse in spain

Effective date: 20181011